AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
Liu C, Huang Y, Qin T, You L, Lu F, Hu D, Xiao R, Qin X, Guo E, Yang B, Li X, Fan J, Li X, Fu Y, Liu S, Wang Z, Dou Y, Wang W, Li W, Yang X, Liu J, Peng W, Zhang L, Cui Y, Sun C, Chen G.
Liu C, et al. Among authors: wang w, wang z.
Cancer Lett. 2022 Mar 1;528:31-44. doi: 10.1016/j.canlet.2021.12.021. Epub 2021 Dec 20.
Cancer Lett. 2022.
PMID: 34942306